IMO it’s self evident that CPAP works. Resmed have built a circa...

IMO it’s self evident that CPAP works. Resmed have built a circa $50 billion business around this widget. Mechanical ventilation is effective but it’s not suitable for everyone, and it doesn’t address the underlying condition.

The exciting part for IHL shareholders is there are no competing drugs in this space. If IHL-42X becomes a genuine treatment in the space then it’s going to be worth billions. Even a modest 10% penetration of Resmed’s market would represent a material market cap for IHL.

GW Pharma had a US$3 billion market cap on Epidiolex pre revenue and they were targeting orphaned conditions of epilepsy. OSA is a much more significant market and its growing an estimated 6% per annum. That’s a golden opportunity.